Journal of the American Academy of Dermatology
Volume 61, Issue 2 , Pages e5-e8 , August 2009

Pregnancy outcomes in psoriasis: Why do we know so little?

  • Elizabeth J. Horn, PhD, MBI

      Affiliations

    • International Psoriasis Council, Dallas, Texas
    • ,
  • Christina D. Chambers, PhD, MPH

      Affiliations

    • Department of Pediatrics, University of California San Diego and Rady Children's Hospital, San Diego, California
    • ,
  • Alan Menter, MD

      Affiliations

    • Department of Dermatology, Baylor University Medical Center, Dallas, Texas
    • ,
  • Alexa B. Kimball, MD, MPH

      Affiliations

    • Departments of Dermatology at Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts
    • Corresponding Author InformationCorrespondence to: Alexa B. Kimball, MD, MPH, Massachusetts General Hospital, 50 Staniford St, #246, Boston, MA 02114.
    • ,
  • International Psoriasis Council

References 

  1. Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol. 2005;141:601–606
  2. Boyd AS, Morris LF, Phillips CM, Menter MA. Psoriasis and pregnancy: hormone and immune system interaction. Int J Dermatol. 1996;35:169–172
  3. Ben-David G, Sheiner E, Hallak M, Levy A. Pregnancy outcome in women with psoriasis. J Reprod Med. 2008;53:183–187
  4. Seeger JD, Lanza LL, West WA, Fernandez C, Rivero E. Pregnancy and pregnancy outcome among women with inflammatory skin diseases. Dermatology. 2007;214:32–39
  5. Chambers CD, Polifka JE, Friedman JM. Drug safety in pregnant women and their babies: ignorance not bliss. Clin Pharmacol Ther. 2008;83:181–183
  6. Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol. 2008;59:295–315
  7. US Food and Drug Administration List of Pregnancy Exposure Registries Available at. http://www.fda.gov/womens/registries/registries.html Accessed February 24, 2009
  8. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–139
  9. National Center for Health Statistics - Birth Data. Available at: http://www.cdc.gov/nchs/births.htm. Accessed February 24, 2009
  10. U.S. Census 2000. Available at: http://www.census.gov/main/www/cen2000.html. Accessed March 16, 2009
  11. Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol. 2007;57:957–962
  12. Briggs GG, Polifka J. Better data needed from pregnancy registries. Birth Defects Res A Clin Mol Teratol. 2009;85:109–111

 Funding for this work was provided by Astellas Pharma, which had no influence on the content or construction of this paper.

 Disclosure: Dr Horn consults with the International Psoriasis Council. Dr Chambers receives grant funding from Amgen, Abbott, Apotex, Bristol-Myers Squibb, Barr Laboratories, Sanofi-Pasteur, Sanofi-Aventis, Sandoz, Kali Laboratories, and TEVA Pharmaceuticals. Dr Menter has served as a consultant, investigator, speaker, or advisory board member for Abbott, Amgen, Astellas, Centocor, Galderma, Genentech, Warner Chilcott, and Wyeth. Dr Kimball has served as a consultant and investigator for Amgen, Centocor, Abbott Laboratories, Neostrata, and Galderma. She is an investigator for Stiefel. She has a fellowship program funded by Centocor.

 Reprint requests should be directed to harvardskinstudies@partners.org.

PII: S0190-9622(09)00554-4

doi: 10.1016/j.jaad.2009.05.004

Journal of the American Academy of Dermatology
Volume 61, Issue 2 , Pages e5-e8 , August 2009

Article Tools